Metastatic breast cancer study shows success in finding new treatment

June 5 2013

Funded by volleyball tournaments, a new study released this week shows success in pinpointing individualized treatment for women with metastatic breast cancer, according to George Mason University researchers.

The Side-Out Foundation's pilot study is part of cutting-edge approach to personalized medicine that looks beyond genomic analysis alone to combine it with what some say is the next frontier in targeted therapy: proteomics.

The pilot study is first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. The trial was announced at the annual meeting of the American Society of Clinical Oncology and is expected to expand into phase two this month. More information about the study can be found here: http://www.side-out.org/ASCOSIDEOUTFINAL.pdf

Standard chemotherapy failed the 25 women who participated in the 2.5-year pilot study, says study co-author Emanuel "Chip" Petricoin, co-director of George Mason's Center for Applied Proteomics and Molecular Medicine. Advanced tumors spread to the liver, brain, bone and other areas in metastatic breast cancer. http://capmm.gmu.edu/

In every case, molecular profiling guided oncologists to a treatment that otherwise would not have been proscribed, says Nicholas Robert, study
co-author and oncologist at Fairfax-based Virginia Cancer Specialists. The pilot study showed that nearly half the patients had at least a 30 percent increase in "progression free survival," which is the time between or during treatment that the cancer is not growing.

"The idea is to turn the tables against cancer by using molecular profiling," says Robert, adding some patients had improvements of four to six months of progression free survival.

"When I first began this trial I was at the end of the breast cancer chemotherapies they had available at the time," says one study participant who has lived with cancer for more than 15 years. "I was not getting better. I was getting worse."

That extra time means the world, says another Side-Out study participant, a Northern Virginia resident who was diagnosed with breast cancer 24 years ago when her children were 1, 3, and 5 years old. She recently attended her youngest son's law school graduation.

"Every time a drug gives me more time, it gives my family and me hope," she says one May morning before going to chemotherapy. Her breast cancer became metastatic in 2001.

Patients are fighting dwindling returns with each new round of treatment. As cancer progresses and patients go on new drug therapies, the time a new therapy stops the cancer from getting worse decreases each time. For example, if a patient responded to one drug for 100 days, the next round of treatment with a different drug typically would keep the cancer in check for less than 100 days and continue to decrease with each new drug therapy.

The Side-Out trial's goal is simple—successful treatment meant patients had to show an increase of progression free survival of at least 30
percent, Petricoin says. Researchers didn't want to just have the patient hold steady but to give them more time. They did—the 30 percent threshold meant 100 days became at least 130 days without tumor growth.

Mason researchers used novel technology developed by them to analyze if the protein drug targets were activated in each tumor. Drugs attack proteins, not the genes, to combat the "molecular defect" that leads to cancerous tumors, Petricoin says. In the past, doctors treated cancer based on their location, not their molecular makeup.

The molecular approach opens up new therapies. For example, if a breast cancer tumor shares the same protein pathway activation found in lung cancer, then the drug developed to hit that target for lung cancer can be used now for breast cancer, Petricoin says. The pilot study only included FDA-approved drugs currently on the market. Additional studies are expected to fold in new drugs as they become available along with experimental drugs, he says.

While Mason researchers unraveled the protein activation maps of the tumor, researchers at Phoenix, Ariz.-based Caris Life Sciences tackled its genomic profile. The two-pronged approach gave the treatment selection committee crucial information on which to base innovative treatments, Robert says.

Speed was essential, Petricoin says. "If you're dying of metastatic disease, you can't wait months for the test results," he says.

The Mason lab tapped a proteomic test that uses technology developed by Petricoin and CAPMM co-founder Lance Liotta to beat their 10-day turnaround goal, frequently cutting the time by four days. The test developed by Mason spin-off Theranostics Health became commercially available to doctors this month (June).
Other firms involved in the study include Spokane, Wash.-based Evergreen Hematology and Oncology, Virginia G. Piper Cancer Center Clinical Trials and Translational Drug Development (TD2), both of Scottsdale, Ariz.

The family of Gloria Dunetz, who died from breast cancer in 2010, started the Fairfax-based Side-Out Foundation in 2004 as a way to raise money for breast cancer research. Gloria's son Rick is a volleyball coach. Side-out is a volleyball term that describes how one team regains the serve or control of the play by scoring a point while its opponent is serving.

As fund-raising increased, Side-Out wanted to promote new research to make a difference in the lives of patients, says Gloria's husband Bryant Dunetz. "We're treating patients in real-time—something that hasn't been done before anywhere in the world," Dunetz says.

Using molecular profiling to target cancer could have far-reaching effects, says Robert, who was Gloria Dunetz's doctor. "It's a story that's being told as we speak," Robert says. "We don't know where it's going to take us."

Provided by George Mason University


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.